Experimental cancer drug GEN1078 tested in just 3 people – trial halted early

NCT ID NCT06771921

Terminated Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an experimental drug called GEN1078 in 3 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check for side effects and see how the body processes the drug. The trial was terminated early, so results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GEN1078 (an experimental drug)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong: This trial was terminated early with only 3 participants, so we have very little data. It is too early to know if GEN1078 is safe or effective, and many early cancer drugs fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT SOLID TUMOR

Contacts and locations

Locations

Centro Integral Oncologico Clara Campal

Madrid, Spain
Clinica Universidad de Navarra

Pamplona, Spain
Hospital Universitari Vall d'Hebron

Barcelona, Spain
Hospital Universitary Fundacion Jimenez Diaz

Madrid, Spain
NEXT Oncology Madrid

Madrid, Spain
Righshospitalet (Copenhagen University Hospital)

Copenhagen, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.